Riskpilot← Back to searchSign inGet full accessVAR2 PHARMACEUTICALS ApS
APSActiveCVR 34621942Nordre Fasanvej 215Research and experimental development on natural sciences and engineering · NACE 7210Est. 201211 employees
Revenue 2024
DKK -22,7M
+2% vs 2023
EBITDA margin
125.8%
-12% vs 2023
Equity ratio
96.6%
Financial strength
Net profit 2024
DKK -21M
-10% vs 2023
| Revenue | DKK -22,7M | +2% |
| EBITDA | DKK -28,6M | -12% |
| Net profit | DKK -21M | -10% |
| Total assets | DKK 66,7M | +12% |
| Equity | DKK 64,5M | +34% |
| Employees | 11 | — |
Legal name
VAR2 PHARMACEUTICALS ApS
CVR number
34621942
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. juni 2012
Share capital
DKK 118.478
Employees
11 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med et bestyrelsesmedlem eller en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er - direkte eller via besiddelse af kapitalandele i andre selskabet - at drive virksomhed indenfor kræftbekæmpelse samt anden virksomhed, der efter direktionens skøn er forbundet dermed.
Address
Nordre Fasanvej 215
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -34 | 68 | -829 | -654 | -1.633 | -3.958 | -1.945 | -4.730 | -3.413 | -4.433 | -6.358 | -22.300 | -22.698 |
| Staff expenses | -0 | -0 | -120 | -170 | -733 | -1.631 | -2.901 | -3.521 | -3.458 | -3.119 | -2.789 | -3.274 | -5.859 |
| EBITDA | -34 | 68 | -949 | -824 | -2.365 | -5.589 | -4.846 | -8.251 | -6.871 | -7.552 | -9.147 | -25.574 | -28.557 |
| Depreciation & amort. | -0 | -0 | -86 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -34 | 68 | -1.035 | -824 | -2.365 | -5.589 | -4.846 | -8.251 | -6.871 | -7.552 | -9.147 | -25.574 | -28.557 |
| Net financials | 0 | -3 | -15 | -25 | -8 | -17 | 52 | -24 | -163 | 79 | 159 | 1.545 | 2.327 |
| Profit before tax | -34 | 66 | -1.050 | -849 | -2.373 | -5.606 | -4.795 | -8.275 | -7.033 | -7.474 | -8.988 | -24.029 | -26.230 |
| Tax | -0 | -0 | -37 | -79 | -516 | -1.227 | -827 | -1.424 | -1.643 | -1.569 | -2.183 | -4.910 | -5.224 |
| Net profit | -34 | 66 | -1.013 | -770 | -1.857 | -4.379 | -3.968 | -6.851 | -5.390 | -5.905 | -6.805 | -19.119 | -21.006 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 93 | 181 | 1.112 | 3.645 | 10.172 | 14.193 | 56.506 | 51.106 | 44.763 | 38.461 | 70.168 | 59.345 | 66.702 |
| Equity | 52 | 118 | 906 | 3.533 | 9.855 | 13.660 | 55.141 | 48.290 | 42.900 | 36.995 | 67.385 | 48.266 | 64.456 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 111 | 290 | 290 | 290 | 290 | 319 |
| Short-term debt | 41 | 64 | 206 | 112 | 317 | 532 | 1.365 | 2.704 | 1.574 | 1.176 | 2.493 | 10.789 | 1.927 |
| Total debt | 41 | 64 | 206 | 112 | 317 | 532 | 1.365 | 2.815 | 1.863 | 1.466 | 2.783 | 11.078 | 2.246 |
EBITDA margin
-2855707200.0%
This company
15.8%
Market median
-18074096303% vs market
20122024
Equity ratio
96.6%
This company
38.2%
Market median
+153% vs market
20122024
Return on equity
-32.6%
This company
18.4%
Market median
-277% vs market
20122024
Net profit margin
-2100601300.0%
This company
8.1%
Market median
-25933349483% vs market
20122024
Asset turnover
-0.34×
This company
1.12×
Market median
-130% vs market
20122024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-06-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AE Management | Management | 2012 | — | — |
UA Management | Management | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2016 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ONCOMAL ApS | Company | 90.0% | 90.0% | 2013 |
Københavns Universitet | Company | 5.0% | 5.0% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ONCOMAL ApS
VAR2 PHARMACEUTICALS ApS Board members of VAR2 PHARMACEUTICALS ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ali El-Salanti | Management | 0 companies |
| Ulf Andreas Linderoth Norlin | Management | 0 companies |
| Peter Schröcksnadel | Board of Directors | 0 companies |
| Poul Henrik Bredahl Sørensen | Board of Directors | 0 companies |
| Mads Daugaard | Chairman | 0 companies |
| Josef Rainer | Board of Directors | 0 companies |
| Silviya Stoykova | Board of Directors | 0 companies |
| Thor Grundtvig Theander | Board of Directors | 0 companies |
| Mai-Britt Zocca | Board of Directors | 0 companies |
| Tanja Rainer | Board of Directors | 0 companies |